Skip to main content

and
  1. Article

    Open Access

    KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy

    Lymph-node (LN) metastasis in prostate cancer (PC) is a main risk factor for tumor recurrence after radical prostatectomy (RP). Molecular analysis facilitates detection of small-volume LN metastases with highe...

    Lukas Lunger, Margitta Retz, Miriam Bandur in Prostate Cancer and Prostatic Diseases (2021)

  2. No Access

    Article

    Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy

    We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP).

    Mark Thalgott, Martina Kron, Johannes M. Brath in World Journal of Urology (2018)

  3. No Access

    Article

    Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer

    The aim of this study was to prospectively evaluate the value of [11C] Choline PET/CT in monitoring early and late response to a standardized first-line docetaxel chemotherapy in castration refractory prostate ca...

    Sarah M. Schwarzenböck, Matthias Eiber in European Journal of Nuclear Medicine and M… (2016)

  4. No Access

    Article

    Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome

    Intraoperative frozen sections (IFS) of the prostate have demonstrated to be effective in reducing positive surgical margins (PSM) and biochemical recurrence (BCR). The aim of this study was to assess partial ...

    Georgios Hatzichristodoulou, Stefan Wagenpfeil, Gregor Weirich in World Journal of Urology (2016)

  5. Article

    Open Access

    Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

    Circulating tumor cell (CTCs) counts might serve as early surrogate marker for treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) patients. We prospectively assessed categorical and ...

    Mark Thalgott, Brigitte Rack, Matthias Eiber, Michael Souvatzoglou in BMC Cancer (2015)

  6. No Access

    Article

    Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients

    The aim of this study was to prospectively compare diffusion-weighted magnetic resonance imaging (DWI) and [11C]choline positron emission tomography/computed tomography (PET/CT) with computed tomography (CT) for ...

    Matthias M. Heck, Michael Souvatzoglou in European Journal of Nuclear Medicine and M… (2014)

  7. Article

    Open Access

    Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

    Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadju...

    Mark Thalgott, Thomas Horn, Matthias M Heck in Journal of Hematology & Oncology (2014)

  8. No Access

    Article

    Detection of circulating tumor cells in different stages of prostate cancer

    To explore circulating tumor cell (CTCs) counts in different stages of prostate cancer (PC) in association with tumor burden, metastatic pattern and conventional serum biomarkers. Overall survival (OS) analyse...

    Mark Thalgott, Brigitte Rack, Tobias Maurer in Journal of Cancer Research and Clinical On… (2013)

  9. No Access

    Article

    Neben wirkungen besser in den Griff bekommen

    Während der fortschreitende Prostatakrebs mit einer Antihormontherapie in Schach gehalten werden soll, bringt der sinkende Testosteronspiegel neue Probleme für den Patienten mit sich. Der folgende Beitrag gibt...

    Mark Thalgott, Jürgen E. Gschwend, Margitta Retz in Uro-News (2011)

  10. No Access

    Article

    So bekommen Sie die Nebenwirkungen besser in den Griff

    Während der fortschreitende Prostatakrebs mit einer Antihormontherapie in Schach gehalten werden soll, bringt der sinkende Testosteronspiegel neue Probleme für den Patienten mit sich. Unsere Autoren geben Ihne...

    Mark Thalgott in MMW - Fortschritte der Medizin (2010)